In this context, ML and DL trained on 18F-FDG PET, Amyloid PET, and Tau PET imaging have shown promise in early diagnosis of AD, in predicting MCI conversion, in tracking disease progression, and in predicting cognitive decline trajectories. Here, MAPT is linked to Alzheimer disease.